4Stankus SJ, Johnson NT. Propyhhiouracil-induced hypersensitivity vasculitis presenting as respiratory failure [J]. Chest, 1992,102 (5) : 1595-1596. 被引量：1
5Fujieda M, Hattori M, Kurayama H, et al. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment[J]. J Am Soc Nephrol, 2002, 13 (2) :437-445. 被引量：1
6Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies [J]. Arthritis Rheum, 2000,43 (2) :405-413. 被引量：1
7Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouacil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Gravesp disease [J]. Thyroid, 2000,10(7) : 595-599. 被引量：1
8Noh JY,Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO- ANCA ) in Graves: disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations[J]. Clin Endocrinol (Oxf) ,2001,54(5) : 651-654. 被引量：1
9Wada N, Mukai M, Kohno M, et al. Prevalence of serum anti- myeloperoxidase antineutrophil cytoplasmic antibodies (MPO- ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole[J]. Endocr J, 2002, 49 (3) : 329-334. 被引量：1
10Zhao MH, Lockwood CM. Azurocidin is a novel antigen for antineutrophil cytoplasmic antibodies (ANCA)in systemic vasculitis [J]. Clin Exp Immunol,1996,103(3):397-402. 被引量：1
